<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04454918</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-906-1007</org_study_id>
    <secondary_id>U1111-1254-4588</secondary_id>
    <nct_id>NCT04454918</nct_id>
  </id_info>
  <brief_title>Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants</brief_title>
  <official_title>A Phase 1 Study to Assess Absolute Bioavailability of TAK-906 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine ABA of TAK-906 following single oral (capsule)&#xD;
      administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose&#xD;
      administration of 100 microgram (μg) (approximately 1 microcurie [μCi]) of [14C]-TAK-906 in&#xD;
      Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a&#xD;
      single oral (solution) administration of 50 mg (approximately 100 μCi) of [14C]-TAK-906 in&#xD;
      Period 2 (absorption, distribution, metabolism, and elimination [ADME]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-906. The study will determine ABA in Period&#xD;
      1, and ADME, and mass balance of TAK-906 after single oral administration in Period 2 in&#xD;
      healthy adult male participants. Plasma and urine samples will be collected for PK&#xD;
      determination; plasma, whole blood, urine, and feces samples will be collected for total&#xD;
      radioactivity (TRA) determination; and plasma, urine, and feces samples will be collected to&#xD;
      characterize the metabolite profiles of TAK-906.&#xD;
&#xD;
      The study will enroll approximately 6 participants. The study is designed to consist of 2&#xD;
      periods: Period 1 (ABA study period) and Period 2 (ADME study period). In Period 1 (ABA study&#xD;
      period), all participants will receive single unlabeled oral 50 mg dose of TAK-906 as capsule&#xD;
      followed by microdose of 100 μg (approximately 1 μCi) [14C]-TAK-906 as intravenous infusion&#xD;
      followed by a washout period of at least 7 days before the dose in Period 2. In Period 2&#xD;
      (ADME study period), all participants will receive a single dose of 50 mg (approximately 100&#xD;
      μCi) [14C]-TAK-906 as an oral solution.&#xD;
&#xD;
      This single center trial will be conducted in the United States. The overall time to&#xD;
      participate in this study is approximately 65 days including screening period. Participants&#xD;
      will be contacted approximately 30 days after the last dose of study drug for a follow-up&#xD;
      assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
    <description>Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: CL: Total Clearance for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-906 Oral Capsule</intervention_name>
    <description>TAK-906 capsule.</description>
    <arm_group_label>TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-TAK-906 Intravenous Infusion</intervention_name>
    <description>[14C]-TAK-906 intravenous infusion.</description>
    <arm_group_label>TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-TAK-906 Oral Solution</intervention_name>
    <description>[14C]-TAK-906 oral solution.</description>
    <arm_group_label>TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Continuous non-smoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to the first dosing and throughout the study.&#xD;
&#xD;
          2. Body mass index (BMI) greater than or equal to (&gt;=) 18.0 and less than (˂) 30.0&#xD;
             kilogram per square meter (kg/m^2) at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. QT interval corrected for heart rate using Fridericia's formula (QTcF) interval is&#xD;
             greater than (&gt;) 450 millisecond (msec) or Electrocardiogram (ECG) findings are deemed&#xD;
             abnormal with clinical significance by the Investigator or designee at screening.&#xD;
&#xD;
          2. Estimated creatinine clearance less than (&lt;) 90 milliliter per minute (mL/min) at&#xD;
             screening.&#xD;
&#xD;
          3. Has tattoo(s) or scarring at or near the site of intravenous (IV) infusion or any&#xD;
             other condition which may interfere with infusion site examination, in the opinion of&#xD;
             the Investigator.&#xD;
&#xD;
          4. Has infrequent bowel movements (less than approximately once per day) within 30 days&#xD;
             prior to first dosing.&#xD;
&#xD;
          5. Has received radiolabeled substances or has been exposed to radiation sources within&#xD;
             12 months of first dosing or is likely to receive radiation exposure or radioisotopes&#xD;
             within 12 months of last dosing such that participation in this study would increase&#xD;
             their total exposure beyond the recommended levels considered safe (that is weighted&#xD;
             annual limit recommended by the International Commission on Radiological Protection&#xD;
             [ICRP] of 3000 milli roentgen equivalent man [mrem]).&#xD;
&#xD;
          6. Has been on a diet incompatible with the on-study diet, in the opinion of the&#xD;
             Investigator or designee, within the 30 days prior to the first dosing and throughout&#xD;
             the study.&#xD;
&#xD;
          7. Donation of blood or significant blood loss within 56 days prior to the first dosing.&#xD;
&#xD;
          8. Plasma donation within 7 days prior to the first dosing.&#xD;
&#xD;
          9. Unable to refrain from or anticipates the use of:&#xD;
&#xD;
               -  Any drug, including prescription and non-prescription medications, herbal&#xD;
                  remedies, or vitamin supplements within 14 days prior to the first dosing and&#xD;
                  throughout the study. Acetaminophen (up to 2 g per 24 hour period) and Milk of&#xD;
                  Magnesia® (that is, magnesium hydroxide [less than or equal to (&lt;=) 60 mL per day&#xD;
                  after Day 3 in Period 1 and after Day 8 in Period 2]) may be permitted during the&#xD;
                  study, only after dosing, if necessary to treat adverse events (AEs). Additional&#xD;
                  administration of Milk of Magnesia® may be administered on other days at&#xD;
                  discretion of the Investigator.&#xD;
&#xD;
               -  Any drugs known to significantly affect the absorption, distribution, metabolism&#xD;
                  or elimination of TAK-906 within 28 days prior to the first dosing and throughout&#xD;
                  the study. Appropriate sources (example, Flockhart Table TM) will be consulted to&#xD;
                  confirm lack of PK/pharmacodynamics interaction with study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <results_first_submitted>September 28, 2021</results_first_submitted>
  <results_first_submitted_qc>December 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2022</results_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT04454918/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT04454918/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 30 July 2020 to 29 September 2020.</recruitment_details>
      <pre_assignment_details>Healthy male participants were enrolled in this study to receive TAK-906 capsule followed by radio-labelled TAK-906 intravenous (IV) infusion on Day 1 of Treatment Period 1 and radio-labelled TAK-906 oral solution on Day 1 of Treatment Period 2. There was a 7-day Washout Period between the two periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-906 50 mg + [14C]-TAK-906 100 μg + [14C]-TAK-906 50 mg</title>
          <description>TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (Day 2 to 8)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2(Day9[Day1of Period2])</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set included all participants who received at least one dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-906 50 mg + [14C]-TAK-906 100 μg + [14C]-TAK-906 50 mg</title>
          <description>TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.30" spread="13.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181.7" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI = weight (kg)/height (m)^2</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.408" spread="2.9179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906</title>
        <description>Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.</description>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion in Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg + [14C]-TAK-906 100 μg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906</title>
          <description>Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.</description>
          <population>Pharmacokinetic (PK) Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion in Period 1 were evaluated for this outcome measure.</population>
          <units>percent absolute bioavailability</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" lower_limit="7.49" upper_limit="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>percentage of dose</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.162" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>percentage of dose</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.44" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>percentage of dose</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.65" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.72" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.293" spread="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>hour (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.62" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.185" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.</population>
          <units>percentage of AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6598" spread="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.288" spread="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.</population>
          <units>hours (hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.892" spread="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.722" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3545" spread="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-906 50 mg</title>
            <description>TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631.3" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>nanogramequivalents/milliliter(ng eq/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.529" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.047" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.976" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.847" spread="137.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>picograms (pg)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3795" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: CL: Total Clearance for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: CL: Total Clearance for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.55" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.04" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>pg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1549" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>percentage of AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3908" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 100 μg</title>
            <description>[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.196" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.81" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.086" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.54" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.111" spread="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.40" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.490" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
          <units>percentage of AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.993" spread="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.013" spread="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-906</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.993" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite (M23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.833" spread="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14430" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1007" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng eq/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.85" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.758" lower_limit="0.51" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.0" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.5" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.3" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.539" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng eq/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.41" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.504" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.17" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>ng eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.25" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2</time_frame>
        <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]-TAK-906 50 mg</title>
            <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration</title>
          <population>PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.964" spread="112.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 30 ± 2 days after last dose of the study drug (Up to approximately 41 days)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety Population included all participants who received at least one dose of the study drug. As prespecified in the protocol data for adverse events was collected and reported for Treatment Period 1 and Treatment Period 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-906 50 mg + [14C]-TAK-906 100 μg</title>
          <description>TAK-906 50 mg, capsule, orally, followed by [14C]-TAK-906 100 μg (approximately 1 μCi), infusion, intravenously, once on Day 1 of Treatment Period 1.</description>
        </group>
        <group group_id="E2">
          <title>[14C]-TAK-906 50 mg</title>
          <description>[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>TrialDisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04454918
org study id: TAK-906-1007
secondary id: U1111-1254-4588
nct id: NCT04454918
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to determine ABA of TAK-906 following single oral (capsule)
      administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose
      administration of 100 microgram (μg) (approximately 1 microcurie [μCi]) of [14C]-TAK-906 in
      Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a
      single oral (solution) administration of 50 mg (approximately 100 μCi) of [14C]-TAK-906 in
      Period 2 (absorption, distribution, metabolism, and elimination [ADME]).
The drug being tested in this study is called TAK-906. The study will determine ABA in Period
      1, and ADME, and mass balance of TAK-906 after single oral administration in Period 2 in
      healthy adult male participants. Plasma and urine samples will be collected for PK
      determination; plasma, whole blood, urine, and feces samples will be collected for total
      radioactivity (TRA) determination; and plasma, urine, and feces samples will be collected to
      characterize the metabolite profiles of TAK-906.

      The study will enroll approximately 6 participants. The study is designed to consist of 2
      periods: Period 1 (ABA study period) and Period 2 (ADME study period). In Period 1 (ABA study
      period), all participants will receive single unlabeled oral 50 mg dose of TAK-906 as capsule
      followed by microdose of 100 μg (approximately 1 μCi) [14C]-TAK-906 as intravenous infusion
      followed by a washout period of at least 7 days before the dose in Period 2. In Period 2
      (ADME study period), all participants will receive a single dose of 50 mg (approximately 100
      μCi) [14C]-TAK-906 as an oral solution.

      This single center trial will be conducted in the United States. The overall time to
      participate in this study is approximately 65 days including screening period. Participants
      will be contacted approximately 30 days after the last dose of study drug for a follow-up
      assessment.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Other
masking: None (Open Label)
measure: Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
description: Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.
measure: Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2
measure: Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2
measure: Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2
measure: Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1
measure: Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: CL: Total Clearance for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906
time frame: Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1
measure: Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2
measure: Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2
measure: Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2
measure: Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2
measure: Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2
measure: Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2
arm group label: TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg
arm group type: Experimental
description: TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
intervention type: Drug
intervention name: TAK-906 Oral Capsule
description: TAK-906 capsule.
arm group label: TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg
intervention type: Drug
intervention name: [14C]-TAK-906 Intravenous Infusion
description: [14C]-TAK-906 intravenous infusion.
arm group label: TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg
intervention type: Drug
intervention name: [14C]-TAK-906 Oral Solution
description: [14C]-TAK-906 oral solution.
arm group label: TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg
criteria: 
gender: Male
minimum age: 19 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Medical Director
role: Study Director
affiliation: Millennium Pharmaceuticals, Inc.
facility: 
country: United States
responsible party type: Sponsor
sharing ipd: Yes
ipd description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
ipd url: https://vivli.org/ourmember/takeda/
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 